Literature DB >> 2121698

Resistance mechanisms of multiresistant serotype 012 Pseudomonas aeruginosa isolated in Europe.

T L Pitt1, D M Livermore, G Miller, A Vatopoulos, N J Legakis.   

Abstract

Serotype 012 Pseudomonas aeruginosa resistant to gentamicin (MIC greater than 4 mg/l) and carbenicillin (MIC greater than 128 mg/l) occur widely in Europe and are homogeneous in their phenotypic and genetic properties. It has been suggested that a single multiresistant strain of this serotype has become widespread. This study examined the resistance mechanisms present in multiresistant serotype 012 P. aeruginosa isolates from Austria, Belgium, France, Greece, Italy, Holland, West Germany and the UK. Disseminated isolates produced a PSE-1 type beta-lactamase, correlating with their resistance to the known substrates of this enzyme (carbenicillin, azlocillin and cefsulodin). These isolates also reacted with gene probes for the aminoglycoside modifying enzymes AAC(6')I and ANT(3'). The probe for AAC(6')I is known to cross-react with the gene for AAC(6')II. The fact that the organisms were resistant to netilmicin, gentamicin, sisomicin and tobramycin, but less so to amikacin, suggested that the latter enzyme was produced rather than AAC(6')I. PSE-1 beta-lactamase and the gene for AAC(6')I/AAC(6')II were absent from the International Antigenic Typing Scheme 012 reference strain, which was sensitive to beta-lactams and aminoglycosides, and also from a multiresistant serotype 012 strain isolated at a London burns unit in 1987. These organisms have been shown previously to be distinct from the disseminated multiresistant strain in their phenotypic properties. Two 012 isolates appeared to have additional resistance determinants to amikacin and isepamicin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121698     DOI: 10.1093/jac/26.3.319

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece.

Authors:  A Tsakris; S Pournaras; N Woodford; M F Palepou; G S Babini; J Douboyas; D M Livermore
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

2.  Infrequent finding of metallo-β-lactamase VIM-2 in carbapenem-resistant Pseudomonas aeruginosa strains from Croatia.

Authors:  Sanda Sardelic; Branka Bedenic; Céline Colinon-Dupuich; Stjepan Orhanovic; Zrinka Bosnjak; Vanda Plecko; Benoit Cournoyer; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

3.  Genotypic homogeneity of nosocomial Pseudomonas aeruginosa O12 strains demonstrated by analysis of protein profiles, DNA fingerprints and rRNA gene restriction patterns.

Authors:  F Grattard; O G Gaudin; B Pozzetto; A Ros; A D Mbida
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-01       Impact factor: 3.267

4.  Study of Pseudomonas aeruginosa serotype O12 isolates with a common antibiotic susceptibility pattern.

Authors:  A Talarmin; P Dubrous; P Gérome; Y Buisson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

5.  Reverse engineering antibiotic sensitivity in a multidrug-resistant Pseudomonas aeruginosa isolate.

Authors:  Julie M Struble; Ryan T Gill
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

6.  Pseudomonas aeruginosa clinical isolates: serotypes, resistance phenotypes and plasmid profiles.

Authors:  M Millesimo; G de Intinis; M G Chirillo; T Musso; D Savoia
Journal:  Eur J Epidemiol       Date:  1996-04       Impact factor: 8.082

7.  Diversity of aminoglycoside resistance in Enterobacter cloacae in Greece.

Authors:  A C Vatopoulos; A Tsakris; L S Tzouvelekis; N J Legakis; T L Pitt; G H Miller; K J Shaw; M Antreou; M Nikolopoulou; Z Komninou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

8.  Survey of susceptibility to selected antibiotics of Pseudomonas aeruginosa strains isolated from patients with tumor disease and their relationship to serotype.

Authors:  B Zatkovic; J Trupl; V Majtán
Journal:  Folia Microbiol (Praha)       Date:  1993       Impact factor: 2.099

9.  Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa.

Authors:  E B Jakics; S Iyobe; K Hirai; H Fukuda; H Hashimoto
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

10.  Diversity of resistance phenotypes and plasmid analysis in multi-resistant 0:12 Pseudomonas aeruginosa.

Authors:  A Tsakris; A C Vatopoulos; L S Tzouvelekis; N J Legakis
Journal:  Eur J Epidemiol       Date:  1992-11       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.